General Overview
FOXO4-DRI is a synthetic senolytic peptide with a D-retro-inverso architecture, first described in 2017 by a research group at Erasmus MC (Rotterdam) in a paper by Baar et al. (journal Cell)[1]. Its key property is the ability to selectively trigger apoptosis in senescent ("aging") cells by disrupting the intracellular interaction between the FOXO4 and p53 proteins, which normally keeps p53 in the nucleus and blocks its pro-apoptotic action. This is not a natural molecule but a rationally engineered research tool.
The 2017 publication should be viewed as a pharmacological analogue of an earlier genetic approach: even before FOXO4-DRI existed, transgenic mouse models with induced clearance of p16Ink4a-positive senescent cells demonstrated that eliminating this cell population delays the development of age-related dysfunctions (for more detail, see the "Cellular Senescence: Context" section). FOXO4-DRI reproduces the same "selective clearance" principle for senescent cells, but through a peptide that can be administered by injection, without genetic modification of the animal.
Research interest in the molecule did not fade after the initial publication: during 2020–2026, FOXO4-DRI was applied in models of age-related testosterone deficiency, cartilage cell biology, keloid scarring, and vascular aging, and was also used as a structural basis for developing the next generation of peptide inhibitors of the FOXO4-p53 interaction. Despite this, the entire evidence base remains preclinical to this day, obtained from human cell cultures, tissue explants, and rodents. No controlled clinical trials involving humans have been conducted, no approved human dose exists, and the compound itself has the status of a research reagent only (RUO, research use only), not intended for use in humans or animals.
Cellular Senescence: Context
Cellular senescence is a stable, essentially irreversible cell-cycle arrest that a cell "chooses" in response to various types of stress: critical telomere shortening and replicative exhaustion, oncogene activation, genotoxic DNA damage (including from cytostatic chemotherapy or irradiation), or oxidative stress. The cycle arrest is implemented through the p16INK4a/Rb and p53/p21CIP1 pathways, and a typical biochemical marker is increased activity of senescence-associated β-galactosidase (SA-β-gal). Critically, a senescent cell does not die: it remains metabolically active while acquiring pronounced resistance to apoptosis.
Beyond resistance to death, senescent cells secrete the so-called senescence-associated secretory phenotype (SASP): a set of pro-inflammatory cytokines (IL-6, IL-1α/β, IL-8, TNF-α), matrix metalloproteinases, and growth factors that alter the tissue microenvironment, recruit immune cells, and can paracrinally induce senescence in neighboring, previously healthy cells (the "bystander effect"). Accumulation of such cells increases with age in virtually all tissues and rises sharply after acute genotoxic insults, such as a course of chemotherapy. It was precisely this model that Baar et al. used to test FOXO4-DRI (see the "Preclinical Studies: In Vivo" section). According to the summary in van Deursen's review (2014, Nature)[3], it was precisely the genetic evidence that eliminating p16Ink4a-positive cells delays age-related tissue dysfunction that became the conceptual foundation for the search for pharmacological ("senolytic") agents capable of reproducing the same effect without genetic modification.
In pharmacological senolytics, according to the review by Kirkland and Tchkonia (2020, Journal of Internal Medicine)[2], several fundamentally different approaches to the selective elimination of senescent cells have emerged, differing in their target and, accordingly, in their profile of limitations.
| Senolytic class | Example | Target / mechanism | Main limitation |
|---|---|---|---|
| Small-molecule combination ("hit-and-run") | Dasatinib + quercetin | Simultaneous inhibition of several senescent-cell anti-apoptotic pathways (SCAP) | Multi-target effect; already has pilot studies involving humans (e.g., for idiopathic pulmonary fibrosis), but with side effects from the parent drugs |
| BCL-2/BCL-XL family inhibitors | Navitoclax | Direct inhibition of the anti-apoptotic proteins BCL-2/BCL-XL | BCL-XL also supports platelet survival → thrombocytopenia as a predictable toxicity |
| Protein-protein interaction-disrupting peptides | FOXO4-DRI | Selective displacement of p53 from the FOXO4-p53 complex | Narrowly targeted mechanism, but with no clinical data involving humans whatsoever |
Molecular Mechanism
In senescent cells, expression of the transcription factor FOXO4 increases, and its forkhead domain (FHD) binds to the intrinsically disordered N-terminal transactivation domain (TAD) of the p53 protein.[9] Structural mapping of this interaction (Zhang R. et al., 2023, Gene & Protein in Disease) showed that a short segment of the FOXO4 forkhead domain (approximately positions 101–109), formed predominantly by hydrophobic contacts, is sufficient to retain most of the binding affinity. It is precisely this minimal recognition motif that constitutes the structural basis reproduced by DRI-class peptides. By holding p53 in the nucleus in this way, FOXO4 prevents its translocation to the mitochondria and thereby blocks the intrinsic (mitochondrial) apoptosis pathway, which would otherwise eliminate the damaged or senescent cell. This is, in effect, the molecular basis of senescent cells' resistance to death, allowing them to persist in tissue as "zombie cells."
FOXO4-DRI, built on the same recognition fragment of the FOXO4 forkhead domain, competes for the same binding surface on the p53 transactivation domain and displaces endogenous FOXO4 from the complex. The released p53 exits the nucleus and redistributes to the mitochondria, triggering the intrinsic apoptosis cascade: according to data from Hu et al. in a model of senescent endothelial cells, this is accompanied by a shift in the balance between pro-apoptotic BAX and anti-apoptotic BCL2 in favor of BAX, as well as an increase in active (cleaved) caspase-3, the final effector protease of the apoptotic cascade.
The role of phosphorylated forms of p53 is documented separately. In endothelial cells subjected to oxidative stress, treatment with FOXO4-DRI was accompanied by increased phosphorylation of p53 at serine-46 together with enhanced export of the protein from the nucleus (Hu et al., 2026).[7] In chronically senescent keloid fibroblasts, another phosphorylated form: p53 phosphorylated at serine-15 (p53-pS15), which is constitutively increased together with p16 in the senescent keloid microenvironment, gradually relocates from the nucleus to the cytoplasm following exposure to FOXO4-DRI: nuclear staining noticeably weakened after approximately two days of treatment and had almost completely disappeared by the third day (Kong et al., 2025).[6] Although the phosphorylation site involved differs depending on cellular context, the general principle, nuclear exclusion of activated p53 as a prerequisite for apoptosis, is observed in both models.
The selectivity of the effect is explained by the fact that increased FOXO4 expression is itself a relatively specific marker of senescence: cells with low baseline FOXO4 levels (proliferating, non-senescent) bind relatively little peptide and largely remain unharmed. This is consistent with results obtained in chondrocytes at different passage numbers and in keloid fibroblast models (see the "In Vitro Studies and Cell Models" section).
Design and Physicochemistry
The abbreviation "DRI" denotes the combination of two independent modifications relative to the natural (all-L) peptide: "retro", reversal of the order of amino acid residues relative to the original sequence, and "inverso", replacement of each residue with its D-stereoisomer. Applied simultaneously to the reversed sequence, these two modifications yield a peptide whose spatial arrangement of side chains approximately reproduces the topology of the original L-peptide (and, accordingly, preserves the binding-surface geometry recognized by the target protein), while the peptide backbone itself is now formed by amide bonds of D-configuration, which natural, L-specific proteases largely do not recognize as a substrate. This confers on the peptide substantial resistance to proteolytic cleavage and, in principle, a longer functional lifetime in biological fluids compared with the equivalent L-peptide.
According to structural reference data (CAS (Chemical Abstracts Service number) registry number 2460055-10-9), FOXO4-DRI is a peptide approximately 47 residues long with the molecular formula C228H388N86O64 and a molecular weight of approximately 5.36 kDa. Its sequence combines a short recognition fragment derived from the FOXO4 forkhead domain (described in the "Molecular Mechanism" section) with a cationic, arginine- and lysine-rich cell-penetrating sequence derived from the HIV-1 TAT protein, a common technique for ensuring cellular and nuclear uptake of peptides that do not themselves cross the membrane.
In research practice, the compound is supplied as a lyophilized powder, which is dissolved immediately before use. In all the rodent studies cited here, the peptide was administered parenterally (intraperitoneally or intravenously) at a dose of approximately 5 mg/kg on an intermittent schedule: roughly once every one to three days rather than continuously, consistent with the general "hit-and-run" dosing logic of senolytics: a short pulse of the drug is sufficient to trigger elimination of the existing pool of senescent cells, after which the effect persists without the continuous presence of the substance. In in vitro studies, the peptide was added directly to the culture medium at concentrations of approximately 25–50 µM (for more detail, see the corresponding section).
The DRI scaffold itself became the starting point for further medicinal-chemistry optimization: Kang et al. (2025, Journal of Medicinal Chemistry)[8], building on structural understanding of the FOXO4-p53 interface, developed a shortened, charge-optimized cationic construct with a cell-penetrating fragment (designated CPP-CAND) that retains the ability to disrupt the FOXO4-p53 interaction and selectivity for senescent cells, while improving on certain properties of the original DRI design. This illustrates that FOXO4-DRI today functions in the literature as a standalone compound and as a validated mechanistic benchmark and structural platform for subsequent development.
Preclinical Studies: In Vivo
The entire available in vivo evidence base for FOXO4-DRI has been obtained exclusively in rodents; there are no data in any other animal species, nor any human dosing data whatsoever, in the peer-reviewed literature.
| Study | Model | Dose / route / duration | Main results |
|---|---|---|---|
| Baar et al., 2017, Cell | Progeroid Xpd(TTD/TTD) mice (nucleotide excision repair deficiency, accelerated aging) and naturally aged mice (p16-3MR reporter line, ~104 weeks) | 3 intravenous injections of 5 mg/kg every other day | Restoration of fur density, motor activity, and responsiveness to stimuli; reduction in plasma urea and creatinine levels (improved renal function) in both models |
| Baar et al., 2017, Cell (chemotoxicity model) | Same mouse line, doxorubicin-induced | 2 intraperitoneal injections of doxorubicin at 10 mg/kg one day apart, followed by FOXO4-DRI on days 1, 3, and 5 | The peptide mitigated signs of doxorubicin-induced chemotoxicity (lower markers of liver damage, better tolerability), one of the first demonstrations that peptide-mediated clearance of senescent cells protects tissue from chemotherapy-induced damage |
| Zhang et al., 2020, Aging | Naturally aged male C57BL/6 mice (20–24 months) versus young controls (3 months) | Intraperitoneal 5 mg/kg every other day, 3 doses; outcomes assessed approximately 30 days later | Significant increase in serum testosterone; reduction in Leydig cell senescence markers (SA-β-gal, p53/p21/p16 proteins); increase in the steroidogenic enzymes 3β-HSD and CYP11A1; reduction in pro-inflammatory SASP cytokines (IL-1β, IL-6, TGF-β); no significant changes in body or testicular weight[4] |
| Hu et al., 2026, Frontiers in Bioengineering and Biotechnology | Naturally aged mice (17 months) and mice with D-galactose-induced accelerated aging | Intraperitoneal 5 mg/kg once every 2 days: 1 month (natural aging) or 4 weeks following a preceding 4 weeks of D-galactose administration (induced model) | Reduction in pulse wave velocity (improved vascular elasticity), decreased aortic wall thickness; reduction in senescence markers (p16, p21, SA-β-gal); increase in the proliferation marker Ki-67; reduction in reactive oxygen species and pro-inflammatory cytokines in vascular tissue |
In all the studies presented, the effects were obtained exclusively with intermittent parenteral administration to rodents; none of the studies establishes an equivalent human dose, and direct extrapolation of the results to the human organism is not currently confirmed.
In Vitro Studies and Cell Models
Studies on human cell cultures and tissue explants extend the mechanism described above to several different cellular systems, but likewise do not establish any dosing regimen suitable for humans.
| Study | Cell / tissue model | Concentration / duration | Main results |
|---|---|---|---|
| Huang et al., 2021, Frontiers in Bioengineering and Biotechnology | Human articular cartilage chondrocytes (8 donors); senescent population: extended culture (PDL9) versus low-passage, non-senescent cells (PDL3) | 25 µM, 5 days in medium with 2% FBS, followed by 2–3 days of recovery in growth medium | The peptide eliminated more than half of the PDL9 population via apoptosis; the proportion of SA-β-gal-positive cells decreased sharply; protein levels of p16, p21, and p53 decreased. Low-passage, non-senescent PDL3 cells were not significantly affected: direct confirmation of the selectivity of the effect[5] |
| Kong et al., 2025, Communications Biology | Human keloid tissue fibroblasts and keloid organ explants (4 mm diameter cylinders obtained by trephine) | 25 µM, 3 days (fibroblasts); explants maintained in culture for up to 10 days | The baseline proportion of keloid fibroblasts arrested in G0/G1 was noticeably higher than in normal fibroblasts; after peptide treatment this proportion decreased substantially in both groups. TUNEL-positive (apoptotic) cells appeared as early as after 3 days of treatment, their number began to decline from day 7, and had almost disappeared by day 10. Nuclear p53-pS15 staining weakened after approximately 48 hours and had almost completely relocated to the cytoplasm by 72 hours |
| Hu et al., 2026 (in vitro component), Frontiers in Bioengineering and Biotechnology | Human umbilical vein endothelial cells (HUVEC); senescence induced by oxygen-glucose deprivation (OGD) | 50 µM, 3 hours (concurrent with OGD exposure) | Reduction in the proportion of SA-β-gal-positive cells, and in p16 and p21 protein levels; increase in the proliferation marker Ki-67; reduction in the DNA damage marker γ-H2AX; reduction in reactive oxygen species levels (by DHE staining) and pro-inflammatory SASP cytokines (IL-1β, IL-6, IL-8, TNF-α). At the molecular level: decreased FOXO4-p53 binding, increased serine-46-phosphorylated p53 and its nuclear export, increased BAX and active caspase-3, decreased BCL2 |
Common to all three models is that apoptosis and cell "clearance" are confined specifically to the senescent subpopulation, while proliferating or minimally passaged cells remain essentially unaffected, consistent with the selectivity mechanism described above. A separate line of in vitro research has focused on mapping the "hotspots" of FOXO4-p53 binding (Zhang R. et al., 2023) and, building on this, developing optimized derivative constructs, including CPP-CAND (Kang et al., 2025), which was tested in models of senescent tumor cells, extending validation of the DRI-class peptide mechanism beyond "classical" senescence models into an oncological context as well.
Human Studies and Clinical Data
No approved human dose of FOXO4-DRI exists, and no completed controlled clinical trial of this compound involving humans has been published in the peer-reviewed literature. All the efficacy data presented above were obtained either in rodents in vivo, or in human cells or tissues studied outside the organism (in vitro, as part of organ explants), but not through administration of the substance to living humans.
This class of peptides is characterized by typical translational barriers. A large, highly charged, non-natural D-peptide has no oral bioavailability and requires parenteral administration. Formal toxicology studies required for clinical trial authorization, immunogenicity assessment (D-peptides, despite their resistance to proteases, theoretically remain a potential antigen upon repeated administration), and human pharmacokinetic characterization have not been published for FOXO4-DRI. By comparison, related small-molecule senolytics such as the dasatinib and quercetin combination already had a history of use and a safety profile from other indications, which allowed them to reach small pilot studies in humans faster than is possible for an entirely new synthetic peptide.
Claims about dosing, "courses," or "anti-aging protocols" for FOXO4-DRI circulating outside the peer-reviewed scientific literature (marketing materials from research peptide suppliers, biohacker forums) are not supported by any published human data and fall outside the scope of this reference material. This section, and the article as a whole, document specifically the preclinical (animal and human cell/tissue) research findings.
Pharmacokinetics and Stability
No human pharmacokinetic parameters (Cmax, Tmax, half-life, clearance, volume of distribution) have been established or published for FOXO4-DRI. All available information is indirect in nature and is inferred from the dosing schedules used in the rodent efficacy studies: in each of them, animals were re-dosed every one to three days rather than once, a schedule more characteristic of a substance with a relatively short functional duration of action in the body than of a long-circulating biologic. However, this is not confirmed by direct serial blood concentration measurement in any published FOXO4-DRI study.
Mechanistically, the peptide's D-retro-inverso backbone should be resistant to cleavage by natural, L-specific exo- and endopeptidases. This is the main rationale for choosing the DRI architecture over a standard L-peptide (see the "Design and Physicochemistry" section). However, resistance to proteases eliminates only one degradation pathway. Other vulnerabilities typical of cationic, arginine- and lysine-rich peptides of this size remain relevant in principle: non-enzymatic degradation pathways (oxidation of sensitive residues, deamidation) and a tendency toward self-aggregation in aqueous solution at higher concentrations, owing to the molecule's strong net positive charge. This is why cold storage and minimizing freeze-thaw cycles are standard recommendations for working with peptides of this class (see the "Analytical Characterization and Handling" section).
No data on oral bioavailability exist, and none is expected a priori given the molecule's size and charge: all published in vivo studies used exclusively parenteral (intraperitoneal or intravenous) administration. No FOXO4-DRI-specific data on tissue distribution, metabolite identification, or renal/hepatic clearance pathways have been published in the literature.
Analytical Characterization and Handling
Research-grade FOXO4-DRI is characterized using standard peptide quality-control methods: reversed-phase high-performance liquid chromatography (HPLC): to assess purity by integrated peak area, and mass spectrometry (typically ESI or MALDI-TOF): to confirm identity by comparing the observed mass with the expected molecular weight (approximately 5.36 kDa, consistent with the formula C228H388N86O64 given in the "Design and Physicochemistry" section). Because the compound is defined precisely by its all-D-amino-acid composition, confirming stereochemical identity (that the material genuinely consists of D- rather than L-residues) in principle requires chiral analytical methods, for example, chiral HPLC or amino acid composition analysis after acid hydrolysis, since D- and L-peptides with an identical sequence are indistinguishable by mass alone.
Handling and storage follow conventions typical for cationic, aggregation-prone research peptides. The material is supplied lyophilized and stored frozen, protected from light and moisture, until reconstitution. After reconstitution (typically in bacteriostatic or sterile laboratory water), the solution is recommended to be aliquoted, stored refrigerated, and used as soon as possible, since the peptide in solution is considerably more vulnerable to hydrolysis and aggregation than the dry lyophilizate; repeated freeze-thaw cycles should be avoided, as they increase both degradation and aggregate formation.
Additional quality parameters relevant specifically to material intended for use with living cell cultures: sterility and endotoxin content testing (e.g., an LAL test), as well as batch certificates of analysis are typically provided by suppliers separately from the peer-reviewed scientific literature, and should be checked for each specific reagent lot before use in sensitive assays.
Research Applications
In laboratory practice, FOXO4-DRI is used as a mechanistically well-characterized "reference" senolytic reagent: to test the causal contribution of senescent cells to a given experimental phenotype, and increasingly also as a structural starting point for developing improved disruptors of the FOXO4-p53 interaction. The literature cited here documents, in particular, the following application areas:
- studies of chemotherapy-induced senescence and the associated tissue damage (doxorubicin chemotoxicity model);
- reproductive and endocrine aging: the role of senescent Leydig cells in age-related testosterone deficiency;[11]
- cartilage cell biology and regenerative engineering: clearance of senescent cells from culture-expanded chondrocytes regarded as material for cartilage cell therapy;
- pathobiology of fibrosis and pathological scarring: the role of senescent fibroblasts in the persistence of keloid tissue;[10]
- vascular aging: the effect of endothelial and vascular senescence on vascular elasticity and function;
- medicinal-chemistry screening and optimization: FOXO4-DRI as a reference structure for mapping the "hotspots" of the FOXO4-p53 interaction and for developing the next generation of peptide inhibitors of this interaction;
- reference/control senolytic in the development of analytical panels of senescence markers and for comparative benchmarking of new senolytic candidates.
In all these contexts, FOXO4-DRI is used exclusively as a laboratory research reagent (RUO). The compound has no established therapeutic indication and is not intended for administration to humans or animals outside a controlled research experiment.